Principal Investigator: Seward Rutkove, MD (Beth Israel Deaconess Medical Center)
Site-PI: Michael Benatar, MD, PhD
This is a longitudinal study designed to assess whether electrical impedance myography (EIM) is a useful measure of disease progression in ALS. EIM is a painless and non-invasive technique that can be used to quantify the biophysical properties of muscle. The study will involve several visits to a study center for serial evaluations. If successful, this study will demonstrate that the use of EIM as an outcome measure would make it possible to complete clinical trials in a shorter period of time and require participation of a small number of people.
- Age ≥ 18 years
- Definite or probable ALS, sporadic or familial
- MRC grade 3/5 or above in at least one limb
- FVC > 70% predicted
- Jeremy Shefner, MD, PhD (SUNY Upstate Medical University)
- Ted Burns, MD (University of Virginia)
- Jim Caress, MD (Wake Forrest University)
- Khema Sharma, MD (University of Miami)
- Nicholas Maragakis, MD, PhD (Johns Hopkins University)
- Eliana Reyes, B.A.
- Sumaira Hussain, B.Sc.
- Email: firstname.lastname@example.org
- Phone: 1-888-413-9315
- Rutkove SB, Caress JB, Cartwright MS, et al. Electrical impedance myography correlates with standard measures of ALS severity. Muscle & Nerve 2014 49(3):441-3. [ PubMed Link ]
- Rutkove SB, Caress JB, Cartwright MS, et al. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler. 2012 Sep;13(5):439-45. [ PubMed Link ]
Lu D, Rutkove S, Gronka S, Spieker A, Usher S, Wuu J, Andersen P, Benatar M. Electrical impedance myography (EIM) findings in pre-symptomatic SOD1+ subjects. Platform presentation at the 9th Annual Northeast ALS Consortium Meeting, Washington, DC, Oct 27-29, 2010
Electrical Impedance Myography as a Pre-Symptomatic Biomarker of ALS. Poster presentation by Sharon Usher at the 20th International Symposium on ALS/MND Meeting, Berlin, December 2009
Back to Research Studies